Cargando…
Inhibition of O‐GlcNAcylation protects from Shiga toxin‐mediated cell injury and lethality in host
Shiga toxins (Stxs) produced by enterohemorrhagic Escherichia coli (EHEC) are the major virulence factors responsible for hemorrhagic colitis, which can lead to life‐threatening systemic complications including acute renal failure (hemolytic uremic syndrome) and neuropathy. Here, we report that O‐Gl...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749473/ https://www.ncbi.nlm.nih.gov/pubmed/34842355 http://dx.doi.org/10.15252/emmm.202114678 |
_version_ | 1784631237003968512 |
---|---|
author | Lee, Kyung‐Soo Lee, Jieun Lee, Pureum Jeon, Bong Chan Song, Min Yeong Kwak, Sojung Lee, Jungwoon Kim, Jun‐Seob Kim, Doo‐Jin Kim, Ji Hyung Tesh, Vernon L Lee, Moo‐Seung Park, Sung‐Kyun |
author_facet | Lee, Kyung‐Soo Lee, Jieun Lee, Pureum Jeon, Bong Chan Song, Min Yeong Kwak, Sojung Lee, Jungwoon Kim, Jun‐Seob Kim, Doo‐Jin Kim, Ji Hyung Tesh, Vernon L Lee, Moo‐Seung Park, Sung‐Kyun |
author_sort | Lee, Kyung‐Soo |
collection | PubMed |
description | Shiga toxins (Stxs) produced by enterohemorrhagic Escherichia coli (EHEC) are the major virulence factors responsible for hemorrhagic colitis, which can lead to life‐threatening systemic complications including acute renal failure (hemolytic uremic syndrome) and neuropathy. Here, we report that O‐GlcNAcylation, a type of post‐translational modification, was acutely increased upon induction of endoplasmic reticulum (ER) stress in host cells by Stxs. Suppression of the abnormal Stx‐mediated increase in O‐GlcNAcylation effectively inhibited apoptotic and inflammatory responses in Stx‐susceptible cells. The protective effect of O‐GlcNAc inhibition for Stx‐mediated pathogenic responses was also verified using three‐dimensional (3D)‐cultured spheroids or organoids mimicking the human kidney. Treatment with an O‐GlcNAcylation inhibitor remarkably improved the major disease symptoms and survival rate for mice intraperitoneally injected with a lethal dose of Stx. In conclusion, this study elucidates O‐GlcNAcylation‐dependent pathogenic mechanisms of Stxs and demonstrates that inhibition of aberrant O‐GlcNAcylation is a potential approach to treat Stx‐mediated diseases. |
format | Online Article Text |
id | pubmed-8749473 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87494732022-01-14 Inhibition of O‐GlcNAcylation protects from Shiga toxin‐mediated cell injury and lethality in host Lee, Kyung‐Soo Lee, Jieun Lee, Pureum Jeon, Bong Chan Song, Min Yeong Kwak, Sojung Lee, Jungwoon Kim, Jun‐Seob Kim, Doo‐Jin Kim, Ji Hyung Tesh, Vernon L Lee, Moo‐Seung Park, Sung‐Kyun EMBO Mol Med Articles Shiga toxins (Stxs) produced by enterohemorrhagic Escherichia coli (EHEC) are the major virulence factors responsible for hemorrhagic colitis, which can lead to life‐threatening systemic complications including acute renal failure (hemolytic uremic syndrome) and neuropathy. Here, we report that O‐GlcNAcylation, a type of post‐translational modification, was acutely increased upon induction of endoplasmic reticulum (ER) stress in host cells by Stxs. Suppression of the abnormal Stx‐mediated increase in O‐GlcNAcylation effectively inhibited apoptotic and inflammatory responses in Stx‐susceptible cells. The protective effect of O‐GlcNAc inhibition for Stx‐mediated pathogenic responses was also verified using three‐dimensional (3D)‐cultured spheroids or organoids mimicking the human kidney. Treatment with an O‐GlcNAcylation inhibitor remarkably improved the major disease symptoms and survival rate for mice intraperitoneally injected with a lethal dose of Stx. In conclusion, this study elucidates O‐GlcNAcylation‐dependent pathogenic mechanisms of Stxs and demonstrates that inhibition of aberrant O‐GlcNAcylation is a potential approach to treat Stx‐mediated diseases. John Wiley and Sons Inc. 2021-11-29 2022-01-11 /pmc/articles/PMC8749473/ /pubmed/34842355 http://dx.doi.org/10.15252/emmm.202114678 Text en © 2021 The Authors. Published under the terms of the CC BY 4.0 license https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Articles Lee, Kyung‐Soo Lee, Jieun Lee, Pureum Jeon, Bong Chan Song, Min Yeong Kwak, Sojung Lee, Jungwoon Kim, Jun‐Seob Kim, Doo‐Jin Kim, Ji Hyung Tesh, Vernon L Lee, Moo‐Seung Park, Sung‐Kyun Inhibition of O‐GlcNAcylation protects from Shiga toxin‐mediated cell injury and lethality in host |
title | Inhibition of O‐GlcNAcylation protects from Shiga toxin‐mediated cell injury and lethality in host |
title_full | Inhibition of O‐GlcNAcylation protects from Shiga toxin‐mediated cell injury and lethality in host |
title_fullStr | Inhibition of O‐GlcNAcylation protects from Shiga toxin‐mediated cell injury and lethality in host |
title_full_unstemmed | Inhibition of O‐GlcNAcylation protects from Shiga toxin‐mediated cell injury and lethality in host |
title_short | Inhibition of O‐GlcNAcylation protects from Shiga toxin‐mediated cell injury and lethality in host |
title_sort | inhibition of o‐glcnacylation protects from shiga toxin‐mediated cell injury and lethality in host |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749473/ https://www.ncbi.nlm.nih.gov/pubmed/34842355 http://dx.doi.org/10.15252/emmm.202114678 |
work_keys_str_mv | AT leekyungsoo inhibitionofoglcnacylationprotectsfromshigatoxinmediatedcellinjuryandlethalityinhost AT leejieun inhibitionofoglcnacylationprotectsfromshigatoxinmediatedcellinjuryandlethalityinhost AT leepureum inhibitionofoglcnacylationprotectsfromshigatoxinmediatedcellinjuryandlethalityinhost AT jeonbongchan inhibitionofoglcnacylationprotectsfromshigatoxinmediatedcellinjuryandlethalityinhost AT songminyeong inhibitionofoglcnacylationprotectsfromshigatoxinmediatedcellinjuryandlethalityinhost AT kwaksojung inhibitionofoglcnacylationprotectsfromshigatoxinmediatedcellinjuryandlethalityinhost AT leejungwoon inhibitionofoglcnacylationprotectsfromshigatoxinmediatedcellinjuryandlethalityinhost AT kimjunseob inhibitionofoglcnacylationprotectsfromshigatoxinmediatedcellinjuryandlethalityinhost AT kimdoojin inhibitionofoglcnacylationprotectsfromshigatoxinmediatedcellinjuryandlethalityinhost AT kimjihyung inhibitionofoglcnacylationprotectsfromshigatoxinmediatedcellinjuryandlethalityinhost AT teshvernonl inhibitionofoglcnacylationprotectsfromshigatoxinmediatedcellinjuryandlethalityinhost AT leemooseung inhibitionofoglcnacylationprotectsfromshigatoxinmediatedcellinjuryandlethalityinhost AT parksungkyun inhibitionofoglcnacylationprotectsfromshigatoxinmediatedcellinjuryandlethalityinhost |